The unsaturated vitamin B12 binding capacity (UBBC) of serum, the three transcobalamins (TC I, TC II, TC III) and serum cobalamin have been studied in adult sickle cell patients with Hb SS. An increase in the level of the binding capacities of TC I and TC III resulting in an increase in UBBC was observed in these patients. There was no difference in the level of the binding capacity of TC II, while there was a significant reduction in the level of serum cobalamin. These changes in the pattern of these binding proteins are discussed in relation to the changes of these binding proteins in paediatric sickle cell patients with Hb SS. The results indicate that the pattern of these binding proteins changes with age among sickle cell patients resulting in an increased level of the binding capacities of TC I and TC III. These increases lend support to the view that these two similar binding proteins are involved in the defence mechanism of the body.

Keywords:
Adult sickle cell patients, Cobalamin, Vitamin B12 binding proteins
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.